BioCentury
ARTICLE | Clinical News

FDA places hold on upcoming Phase I for point-of-care CAR Ts

June 22, 2018 5:58 PM UTC

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing. Ziopharm was down $0.79 (18%) to $3.51 on June 18.

The therapy, produced using Ziopharm's Sleeping Beauty non-viral integration technology, comprises CD19-targeted CAR T cells co-expressing membrane-bound IL-15 and a control switch...